Oxiperomide

Oxiperomide

Clinical data
Routes of administration	Oral
Identifiers
IUPAC name 3-[1-(2-phenoxyethyl)piperidin-4-yl]-1H-benzimidazol-2-one
CAS Number	5322-53-2
PubChem CID	68634
ChemSpider	61893
UNII	WRO75M6RW2
KEGG	D02676
ChEMBL	ChEMBL2059304
CompTox Dashboard (EPA)	DTXSID30201306
Chemical and physical data
Formula	C20H23N3O2
Molar mass	337.423 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCOC4=CC=CC=C4
InChI InChI=1S/C20H23N3O2/c24-20-21-18-8-4-5-9-19(18)23(20)16-10-12-22(13-11-16)14-15-25-17-6-2-1-3-7-17/h1-9,16H,10-15H2,(H,21,24) Key:NVDBBGBUTKLRSN-UHFFFAOYSA-N

Oxiperomide is an antipsychotic. ^[1] Clinical trials demonstrated that it can reduce dyskinesia in patients with Parkinson's disease who are taking dopamine agonists without increasing Parkinsonian symptoms. It does this by selectively antagonizing dopamine receptors. ^{[2] [3]} Further development of this drug is not available. It appears to have never been marketed.

See also

• Benperidol
• Neflumozide

References

1. Elks J (1990). "Oxiperomide". The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Dordrecht: Springer. ISBN   978-1-4757-2085-3.
2. Bédard P, Parkes JD, Marsden CD (April 1978). "Effect of new dopamine-blocking agent (oxiperomide) on drug-induced dyskinesias in Parkinson's disease and spontaneous dyskinesias". British Medical Journal. 1 (6118): 954–956. doi:10.1136/bmj.1.6118.954. PMC   1603806 . PMID   638546.
3. Casey DE, Gerlach J (March 1980). "Oxiperomide in tardive dyskinesia". Journal of Neurology, Neurosurgery, and Psychiatry. 43 (3): 264–267. doi:10.1136/jnnp.43.3.264. PMC   490519 . PMID   7373324.